title: Risk factors associated with hypersensitivity reactions to cetuximab: anti-cetuximab IgE detection as screening test.
abstract: OBJECTIVE
  To describe the factors associated with a high risk of a hypersensitivity reaction to cetuximab.
  
  
  METHODS
  We retrospectively studied a cohort of patients living in Normandy (France) treated with cetuximab.
  
  
  RESULTS
  Among the 229 treated patients, 24 (10.5%) had a hypersensitivity reaction to cetuximab, including 11 grade 3-5 reactions. Detection of anti-cetuximab IgE could be performed in 108 patients. Anti-cetuximab IgE was found in 13 of 17 patients (76.5%) who had a hypersensitivity reaction to cetuximab compared with 17 of 91 control patients (18.7%; adjusted odds ratio: 14.99; 95% CI: 3.59-62.63). No clinical criteria predicted the risk of allergy to cetuximab.
  
  
  CONCLUSIONS
  Anti-cetuximab IgE may help physicians identify patients at risk of a hypersensitivity reaction to cetuximab.
authors.affiliation: Department of Hepato-Gastroenterology & Nutrition, Caen University Hospital, Avenue Côte de Nacre, CHU Côte de Nacre, 14033 Caen cedex 9, France.
authors.forename: Benoît
authors.initials: B
authors.lastname: Dupont
authors.forename: Delphine
authors.initials: D
authors.lastname: Mariotte
authors.forename: Bénédicte
authors.initials: B
authors.lastname: Clarisse
authors.forename: Marie-Pierre
authors.initials: MP
authors.lastname: Galais
authors.forename: Karine
authors.initials: K
authors.lastname: Bouhier-Leporrier
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Grellard
authors.forename: Brigitte
authors.initials: B
authors.lastname: Le Mauff
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Reimund
authors.forename: Radj
authors.initials: R
authors.lastname: Gervais
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000068818:Cetuximab; D004342:Drug Hypersensitivity / Q000175:diagnosis / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005602:France; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology*; D012189:Retrospective Studies; D012307:Risk Factors; D012720:Severity of Illness Index
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007073:Immunoglobulin E; D000068818:Cetuximab
keywords: anaphylaxis; anti-IgE antibodies; cetuximab; colonic neoplasms; head and neck neoplasms; hypersensitivity